Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8554367 | 0.92 | SIRT2 (0.47) | SIRT2MAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL9965035 | 0.78 | SMN1; SMN2 (0.44) | SIRT2MAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL24451759 | 0.77 | HDAC2 (0.43) | MAPTCYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL24259026 | 0.77 | SIRT2 (0.39) | SIRT2MAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL24452449 | 0.77 | MAPT (0.38) | SIRT2MAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL5766231 | 0.76 | MAPT (0.43) | SIRT2MAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL4741952 | 0.76 | SIRT2 (0.49) | SIRT2MAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL31532293 | 0.74 | ALDH1A1 (0.56) | MAPTCYP2C9CYP2C19SMN1; SMN2HSD17B10 | |
| SCHEMBL24258699 | 0.74 | MAPT (0.39) | SIRT2MAPTCYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL24452417 | 0.73 | HDAC1 (0.43) | MAPTCYP2C9CYP2C19SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | SIRT2 2746/4885MAPT 398/4885CYP2C9 1096/4885 |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | SIRT2 2746/4885MAPT 398/4885CYP2C9 1096/4885 |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | SIRT2 3286/4885MAPT 510/4885CYP2C9 814/4885 |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | SIRT2 2746/4885MAPT 398/4885CYP2C9 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.